Search the Newsreel

Viyash Scientific profit doubles in Q1FY27; eyes Italy deal

Cytek (CTKB) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer - Wenbin Jiang Chief Financial Officer - William McCombe Investor Relations - Mark Meehan Full Conference Call Transcript Operator: Hello, and thank you for standing …

Harmony Biosciences (NASDAQ:HRMY) Rating Increased to Strong-Buy at Wall Street Zen

Wall Street Zen has upgraded Harmony Biosciences (NASDAQ:HRMY) from a "buy" to a "strong-buy" rating. This upgrade comes as the company reported strong quarterly earnings, beating analyst estimates with an EPS of $1.28 and a 30.3% year-over-year revenue increase to $261.28 million. Despite this, …

What Arcus Biosciences (RCUS)'s Steep Revenue Drop and 2026 Guidance Cut Means For Shareholders

Why Cogent Biosciences (COGT) Is Down 10.5% After Reporting Wider First-Half 2026 Losses – And What's Next

Nectar Lifesciences Publishes Q1 FY2026 Results in Press and Online

Why Alto Neuroscience (ANRO) Is Up 13.5% After Expanding ALTO-207 Phase 3 And Securing New Funding

Alto Neuroscience (ANRO) saw a 13.5% stock increase after expanding its ALTO-207 Phase 3 trial for treatment-resistant depression and securing approximately $100 million in new funding. Despite ongoing net losses, the company aims to validate its data-driven approach, with short-term focus on the expanded …

Trading the Move, Not the Narrative: (INBX) Edition

This article provides an in-depth analysis of Inhibrx Biosciences Inc (INBX), highlighting strong sentiment across all time horizons and an exceptional 100.9:1 risk-reward setup. It outlines three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide trading decisions.

Ck Life Sciences Int'l., (Holdings) - LSI - Stock Price & News

How Investors Are Reacting To Forte Biosciences (FBRX) Widening Losses But Slightly Improved Per-Share Results

Forte Biosciences reported increased net losses in Q2 and H1 2026 but saw a slight improvement in basic loss per share due to share count adjustments. The company's investment narrative is now heavily tied to its pending sale to argenx and the cash tender …

Mill Capital Management LLC Invests $9.85 Million in Boston Scientific Corporation $BSX

Mill Capital Management LLC has invested $9.85 million in Boston Scientific Corporation, acquiring 230,815 shares. Institutional investors collectively own 89.07% of the company's stock, and despite a recent growth slowdown in key businesses, analysts maintain a "Moderate Buy" consensus rating with an average price …

CSTL (CSTL) insider and family trusts detail planned and recent stock sales

A recent SEC Form 144 filing indicates a planned sale of 25,792 shares of CSTL common stock, valued at $763,959.04, by an insider and related family trusts, to be executed around August 14, 2026, through Goldman Sachs & Co. LLC. The filing also details …

Walleye Capital LLC Acquires Shares of 347,898 Tyra Biosciences, Inc. $TYRA

Walleye Capital LLC has acquired a new stake of 347,898 shares in Tyra Biosciences, Inc. (NASDAQ:TYRA), valued at approximately $11.1 million, bringing institutional ownership in the company to 84.14%. Despite the stock opening at $25.29, well below its 52-week high, analysts maintain a "Moderate …

Walleye Capital LLC Buys Shares of 386,183 IDEAYA Biosciences, Inc. $IDYA

Walleye Capital LLC has acquired 386,183 shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) during the second quarter, a new stake valued at approximately $14.4 million. This purchase represents 0.44% of IDEAYA Biosciences. Despite a reported quarterly loss of $1.22 per share, institutional ownership of the …

Forte Biosciences, Inc. (NASDAQ:FBRX) Given Average Recommendation of "Hold" by Brokerages

Forte Biosciences, Inc. (NASDAQ:FBRX) has received an average "Hold" rating from seven brokerages, with an average 12-month price target of $72.50, below its current $76.83 stock price. Recent analyst coverage has generally been negative, including downgrades from Wall Street Zen, Weiss Ratings, Barclays, and …

Value Partners Investments Inc. Reduces Holdings in Thermo Fisher Scientific Inc. $TMO

California State Teachers Retirement System Has $1.12 Million Stock Holdings in Kodiak Sciences Inc. $KOD

Assembly Biosciences, Inc. (NASDAQ:ASMB) Given Average Recommendation of "Moderate Buy" by Brokerages

Assembly Biosciences (NASDAQ:ASMB) has received an average "Moderate Buy" recommendation from brokerages, with five out of seven analysts rating the stock a buy. The average 12-month price target for ASMB is $44.00, significantly higher than its recent price of $32.95. The company also reported …

Security National Bank Boosts Stock Position in Thermo Fisher Scientific Inc. $TMO

Security National Bank increased its stake in Thermo Fisher Scientific Inc. (TMO) by 18.5% in the second quarter, bringing its total holdings to 14,095 shares valued at approximately $7.1 million. The article also notes that institutional investors own 89.23% of TMO, and analysts generally …

Gufic Biosciences Q1 Results: Net profit up 23% YoY to ₹80 crore

Everett Harris & Co. CA Acquires Shares of 80,341 Edwards Lifesciences Corporation $EW

Everett Harris & Co. CA has purchased 80,341 shares of Edwards Lifesciences Corporation (NYSE:EW) for approximately $7.27 million during the second quarter, marking a new stake in the company. This comes as other institutional investors have also adjusted their holdings in the medical research …

California State Teachers Retirement System Purchases 21,011 Shares of MBX Biosciences, Inc. $MBX

The California State Teachers Retirement System significantly increased its stake in MBX Biosciences by 1,197.9%, now holding 22,765 shares valued at $680,000. Other institutional investors also raised their positions in the company. Despite the company missing its Q2 earnings estimates, analysts maintain a "Moderate …

Dimensional Fund Advisors LP Invests $1.40 Million in MBX Biosciences, Inc. $MBX

Dimensional Fund Advisors LP has acquired a new stake worth $1.40 million in MBX Biosciences, Inc., representing 0.10% of the company. Other institutional investors have also increased their positions in MBX. Despite missing earnings estimates for the recent quarter, analysts generally maintain a "Moderate …

Cannon Advisors Inc. Acquires New Shares in Thermo Fisher Scientific Inc. $TMO

Cannon Advisors Inc. recently purchased 3,971 shares of Thermo Fisher Scientific Inc. (NYSE:TMO) valued at approximately $2.12 million, making it their 17th biggest position. This acquisition comes as other hedge funds have also adjusted their holdings in TMO, while company insiders have sold a …

Canoe Financial LP Buys 148,999 Shares of Thermo Fisher Scientific Inc. $TMO

Abundance Wealth Counselors Grows Stake in Gilead Sciences, Inc. $GILD

Abundance Wealth Counselors significantly increased its stake in Gilead Sciences, Inc. by 93.7% in the second quarter, now holding 22,139 shares valued at $2.8 million. This comes as Gilead reported strong Q2 revenue growth of 10.6% to $7.8 billion, driven by its HIV franchise …

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Rating of "Moderate Buy" from Brokerages

IDEAYA Biosciences (NASDAQ:IDYA) has received an average rating of "Moderate Buy" from sixteen brokerages, with an average 12-month price target of $50.13, significantly above its current share price of $36.30. The company's recent quarterly results showed revenue exceeding expectations but missed on earnings per …

Handelsbanken Fonder AB Has $6.27 Million Position in Roivant Sciences Ltd. $ROIV

Handelsbanken Fonder AB significantly increased its stake in Roivant Sciences Ltd. during the second quarter, now holding 177,209 shares valued at $6.27 million. Institutional investors collectively own 64.76% of Roivant's stock, despite recent insider selling totaling approximately 2.06 million shares. Analysts maintain a "Moderate …

Science Applications International Corporation $SAIC Shares Acquired by Bank of America Corp DE

Bank of America Corp DE increased its stake in Science Applications International Corporation (SAIC) by 17.5% in the first quarter, acquiring an additional 56,720 shares, bringing its total to 380,538 shares valued at $36.1 million. The company's stock is primarily held by institutional investors, …

Nectar Lifesciences to Relocate Corporate Office Within Chandigarh Industrial Hub

T. Rowe Price Associates (TWST) discloses 3.63M-share Twist Bioscience position

T. Rowe Price Associates has reported a beneficial ownership of 3,634,470 shares of Twist Bioscience Corp. (TWST), representing a 5.8% stake in the company's common stock. The firm holds sole voting power over 3,520,536 shares and sole dispositive power over all 3,634,470 shares, as …

Precision Trading with Wave Life Sciences Ltd. (WVE) Risk Zones

This article from Stock Traders Daily provides a detailed analysis of Wave Life Sciences Ltd. (WVE), highlighting weak sentiment across all horizons supporting a short bias. It outlines institutional trading strategies, including long, breakout, and short positions, with specific entry zones, targets, and stop …

Gilead Sciences (NASDAQ:GILD) Upgraded to "Buy" at Wall Street Zen

Wall Street Zen has upgraded Gilead Sciences (NASDAQ:GILD) from a "Hold" to a "Buy" rating. This upgrade aligns with a "Moderate Buy" consensus among analysts, with an average price target of $158.04. The company recently reported strong quarterly results, exceeding revenue expectations, despite some …

Wall Street Zen Downgrades Kodiak Sciences (NASDAQ:KOD) to Sell

Wall Street Zen downgraded Kodiak Sciences (NASDAQ:KOD) from "hold" to "sell" on Saturday, despite the broader analyst consensus being a "Moderate Buy." The company's shares opened near their 52-week high at $41.35, but Kodiak Sciences reported a larger-than-expected quarterly loss of $1.05 per share. …

IDEAYA Biosciences (NASDAQ:IDYA) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen downgraded IDEAYA Biosciences (NASDAQ:IDYA) from "hold" to "sell," despite the broader analyst consensus remaining a "Moderate Buy" with an average price target of $50.12. The company's shares opened at $36.30, and it recently reported a quarterly loss of $1.22 per share, …

TriSalus Life Sciences (NASDAQ:TLSI) Cut to "Sell" at Wall Street Zen